Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > New Hire

<< Previous

Bullboard Posts

Next >>

Comment by Hideawayon Jan 07, 2021 9:52am

147 Views

Post# 32241097

RE:RE:RE:New Hire

Agree that today"s appointment is another positive for ATE but we will require solid info on the path forward before we commence a substained march north.
Mugs, on Monday you suggested a comprehensive shareholder update could be out tomorrow. Hope it materializes. Do you still feel we will get it tomorrow? Not sure Friday's are a prime time to release such an anticipated release.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments